1-4 of 4
Tapas Ranjan Behera
Close
Sort by
Journal Articles

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Rajshekhar Chakraborty, Tapas Ranjan Behera, Hong Li, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Allison Winter, Faiz Anwer, Brad Pohlman, Ronald M. Sobecks, Betty K. Hamilton, Navneet S. Majhail
Journal: Blood
Blood (2022) 140 (Supplement 1): 10926–10927.
https://doi.org/10.1182/blood-2022-166904
Published: 2022
Journal Articles

Demographics and Outcomes of Multiple Myeloma Patients Undergoing Modern Modality Treatments Proceeding to ASCT: A Retrospective Study

Shubham Adroja, Arslan Babar, Muhammad Ali, Gauranga Mahalwar, Taeyeong Ko, Ashish Kumar, Tapas Ranjan Behera, Doaa Attia, Fatima Babar, Faiz Anwer
Journal: Blood
Blood (2021) 138 (Supplement 1): 4743.
https://doi.org/10.1182/blood-2021-154070
Published: 2021
Journal Articles

Defining Quality Though a Collaborative Process for Multiple Myeloma Care

Arslan Babar, MD, Tapas Ranjan Behera, MD, Syed Maaz Abdullah, MBBS, Imtisaal Waris, Saher Nasir Amin, MD, Adeel Masood, MD, Faiz Anwer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-142774
Published: 2020
Journal Articles

Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Somedeb Ball, MD, Tapas Ranjan Behera, Sariya Wongsaengsak, MD, Nuvneet Khandelwal, MD, Rajshekhar Chakraborty, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1841.
https://doi.org/10.1182/blood-2019-125464
Published: 2019